The Latest Cardiac and Vascular News
Treatment Supported by Evidence from Multiple Studies and Renal Denervation Position Paper from the European Society of Hypertension PALO ALTO, Calif. & FRANKFURT, Germany–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the company’s Paradise™ Ultrasound Renal Denervation System (the “Paradise™ […]
Unique, Delayed-Release Formulation of Imatinib Designed to Avoid Gastric Intolerance On Track to Initiate a Single Phase 3 in PAH in 2Q 2022 Recently Updated Company Website Highlights Imatinib Clinical Program MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary […]
Baylis Medical Technologies to increase investment in radiology and neurosurgery business in Canada MISSISSAUGA, Ont. (October 6, 2021) – Baylis Medical Company Inc. is pleased to announce it has reached an agreement to sell its cardiology business to Boston Scientific Corporation. The acquisition, for an upfront payment of $1.75 billion […]
MARLBOROUGH, Mass.–(BUSINESS WIRE)–GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to remove hypersensitivity to ‘blood and blood products’ from the contraindications in its prescribing information for its product OptisonTM (Perflutren Protein-Type A Microspheres Injectable Suspension, USP). Optison is an ultrasound enhancing agent […]
SEOUL, South Korea, Oct. 5, 2021 /PRNewswire/ — South Korean artificial intelligence (AI) developer, VUNO Inc., announced today that the company closed a deal with global medical device manufacturer, Samsung Electronics Co., Ltd., to embed VUNO’s artificial intelligence-driven chest X-ray diagnostic solution, VUNO Med®-Chest X-ray™ into Samsung’s GC85A premium ceiling type digital […]
BOSTON, Oct. 5, 2021 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced the closing of its previously announced registered direct offering of 4,307,693 shares of the Company’s common stock, at a purchase price of $3.25 per share. […]
Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The data […]
LAS VEGAS, Oct. 5, 2021 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the first round of 16 highly anticipated late-breaking clinical trial results at VIVA121 hosted at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is an […]
ST. LOUIS PARK, Minn., Oct. 04, 2021 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced successful completion of the first-in-human procedure with the NeoChord NeXuS Transcatheter Mitral Chordal Repair technology (TMVr). […]
Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar […]
